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Purpose or Objective: Radiotherapy (RT) is one of the most 
important curative options for treating localized prostate 
cancer (PC). At low α/β ratio of prostate tumors, HDR-
brachytherapy (HDR-BT) represents a way to perform an 
absolute and radiobiologic dose escalation. When using 3-D 
real-time planning systems it is possible to optimize 
treatment plans generating dose distributions with an 
integrated boost (SIB) to peripheral zone (PZ) without 
substantially increasing the dose to the organs at risk (OAR), 
especially the urethra. 
Aim: to analyze the dosimetric parameters (DP) and the 
acute toxicity of 30 consecutive patients (pts) treated with 
HDR-BT and a SIB to the PZ. 
 
Material and Methods: From January 2014 to September 
2015, 20 pts with intermediate/high risk PC were treated 
with combined external beam RT (EBRT 50 Gy/25 f) and HDR-
BT (2 x 9 Gy in the 2nd and 4th week of the EBRT). In the 
same period, 10 pts with low risk PC were treated with HDR-
BT monotherapy (3 x11.5 Gy, every 2nd week). In all implants 
a SIB of 20% (EBRT+HDR-BT) or 15% (HDR-BT monotherapy) to 
the PZ was planned. Equivalent dose at 2 Gy / fraction 
(EQD2), using α/β of 1.5 for target volumes and 3 for OAR, 
were calculated. 
 
Results: Median age was 68 years (range 56-76). DP are 
presented in table 1. In 33/40 implants in pts with 
EBRT+HDR-BT dose-escalation to the PZ was reached (range 6 
–44% of the prescribed dose). The median V100 for the 
prostate was 94.5% (CI ±1.6%). in 26/30 of the implants in pts 
with HDR-BT monotherapy the intended dose-escalation was 
reached (range 6 – 40% of the prescribed dose). The median 
V100 for the prostate was 92.8% (CI ±2.2%). No grade ≥3 
toxicity was observed. Grade 2 toxicity was 13% and resolved 
within 1 month in 90% of the pts. 
 
 
Conclusion: HDR-BT with SIB to the PZ is feasible in both 
combined and monotherapy settings. Acute toxicity was mild. 
Local control and late toxicity profile should be investigated 
prospectively. 
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Purpose or Objective: This prospective longitudinal study 
quantifies patient reported Quality of Life (QoL) pre-
treatment and up to ten years following permanent I-125 
prostate brachytherapy delivered as monotherapy in a single 
institution  
 
Material and Methods: 120 patients were asked to complete 
the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire, a comprehensive validated QoL tool designed 
to evaluate patient function and bother after prostate cancer 
treatment. Men completed the EPIC questionnaire before 
brachytherapy and at 8 time points after treatment (6 weeks; 
6,10 and 18 months; 2,3,5, and 10 years). At each time point 
clinically relevant small, moderate and severe declines in 
QoL were defined as 0.2-0.5 times SD, 0.5-0.8 times SD and > 
0.8 times SD of baseline function for each of urinary, bowel 
and sexual domains respectively. 
 
Results: Response rates in the first two years were >90% but 
thereafter dropped to 75% at 5 years and 48% at 10 years. 50 
patients (41.6%) responded at all stages. Maximal 
deterioration in mean urinary and sexual summary scores was 
noted 6 weeks after implant with severe urinary symptoms 
and moderate bowel/sexual symptoms at that point. At 6 
months urinary and bowel QoL had improved to mild 
impairment which then fully resolved by 10 months. Sexual 
QoL remained mildly impaired throughout the 10 years. At 10 
years new mild impairment of urinary and bowel QoL was also 
found. 
 
Conclusion: Clinically mild changes in urinary, bowel and 
sexual QoL are found 10 years after I-125 monotherapy. The 
impairment in sexual function persists from treatment but 
urinary and bowel symptoms are new at 10 years and may be 
either a late effect of brachytherapy or due to increasing 
age. 
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Purpose or Objective: Purpose: to evaluate the impact of 
the “image-guided” technology evolution on the implant 
quality in the interstitial brachytherapy with 125I seeds in 
the treatment of the prostate cancer. 
 
Material and Methods: Methods and materials: from April 
2004 until May 2014 we treated 306 patients with prostate 
cancer with permanent brachytherapy implants of radioactive 
125I seeds with a prescription dose of 145 Gy. The technology 
is changed during the years and we identify 4 groups relative 
to each different image-guided method. Group 1: 107 
implants from April 2004 until January 2007 using ultrasound 
guide in the transverse plane, fluoroscopic check and 
planning with 3D Prowess TPS; Group 2: 76 patients until 
October 2008 with Variseed 8.0 TPS and ultrasound both for 
transverse and longitudinal guide; Group 3: 43 patients until 
February 2010 with a “real-time” ultrasound guide both for 
transverse and longitudinal guide; Group 4: 80 patients with a 
new delivery system to assembly seed trains (Quicklink, 
BARD). For each group we calculate the mean D90 in the 
“postplanning” (evaluated on CT images after 60 days) and 
the difference between planning and postplanning in terms of 
D90 and V100 (dose fall-off). In the last group we evaluate 
also the difference, in terms of D90, V100 and maximum 
urethra dose between the theoretical planning and the 
effective implant, evaluated in the operating room on the 
ultrasound images at the end of the surgery. 
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Results: Results: in the 4 groups the results in terms of D90 
are respectively 123±32Gy, 146±28Gy, 153±23Gy, 166±17Gy, 
as shown in Figure 1. The dose fall-off in terms of D90 is 
respectively 58Gy, 43Gy, 37Gy, 21Gy (as shown in Figure 2) 
and in terms of V100 17%, 10%, 8%, 4%. In the last group the 
mean theoretical D90 and V100 are 187Gy and 99%, against a 
real implant evaluation of 186Gy and 99%and the maximum 
urethra dose is 210Gy in the planning and 219Gy at the end of 
the implant. In the 30% of the patients of the “real-time” 
group we changed the number of seeds or needles 
composition during the implant, to reach the desired 
constraints and PTV coverage. 
 
 
Conclusion: Conclusion: our work shows the impact of the 
“image-guided” technology evolution on the dose fall-off 
both in terms of D90 and V100. Moreover, we show how the 
“real-time” method allows to change the “theoretical” plan 
during the implant, to reach the recommended constraints 
and PTV coverage [1]. 
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Purpose or Objective: We initially reported biochemical 
control rate of 97% at 4 years of followup (Brachytherapy, 
2009), which highlighted our methodology of limiting needle 
trauma, relying on Intra-operative, Real-Time computer 
assisted IO (Inverse Optimization) to reduce the number of 
sources and total activity without compromising dosimetric 
quality. This update was performed to confirm our earlier 
favorable BFFS outcomes. 
 
Material and Methods: Between 2001 and 2013, 491 patients 
underwent real-time IO-PSI. Only patients with a minimum of 
2 years of follow-up treated without supplemental IMRT were 
the subject of this analysis (N=315). Our dose objectives and 
constraints for real-time IO-PSI have previously been 
published and remain unchanged. The main dose objective 
intra-operatively was to achieve a V100 > 95% (Volume 
receiving > 95% of the prescribed dose). Patients were 
implanted with either 125I (PD=145 Gy) or 103Pd (PD =120 Gy). 
Toxicity was prospectively scored using the Radiation 
Oncology Group Toxicity scale and the International Prostate 
Symptom Score questionnaire. Biochemical control was 
determined using the nadir+2 ng/ml definition.  
 
Results: The mean and median followup was 58 and 54 
months respectively (range: 24-110 months). The NCCN risk 
classification for FR and IR patients were used. 125I sources 
were used for 93% of the implants, and 103Pd for 7%. 89% of 
patients presented with FR disease while 10% presented with 
IR, and in 2 cases HR. (1%). The median number of sources 
and total activity implanted were 65 and 999MBq, 
respectively. The median prostate volume implanted was 36 
cc. The median V100 was 95%. Absolute BNED was 97%. The 
10 year actuarial probability of biochemical control rate for 
all patients was 95%, with no difference observed between FR 
or IR patients (97% and 95% respectively) Late Gu and GI 
Grade 2 and higher toxicity was very low. With a minimum 
follow-up for 2 years, the late Grade 2 and Grade 3 GU 
toxicity was 19% and 1% respectively. The late Grade 2 and 3 
rectal bleeding rate was 1% and 0% respectively, with no 
Grade 4 toxicity observed.  
 
Conclusion: With extended follow-up of 10 years, real-time 
IO-PSI demonstrated excellent biochemical control rates with 
low incidence of toxicity confirming the validity of our 
original hypothesis and methodology of Inverse planning in 
real time for PSI, and comparing favorably to other 
alternatives at lower cost in the USA. 
 
 
 
 
Poster: Radiobiology track: Molecular targeted agents and 
radiotherapy  
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Purpose or Objective: Despite aggressive treatment with 
radiation therapy plus temozolomide (TMZ), the prognosis for 
glioblastoma remains poor. We investigated the potential of 
targeting signal transducer and activator of transcription-3 
(STAT3) to improve the therapeutic outcome of glioblastoma. 
 
Material and Methods: We evaluated the preclinical 
potential of a STAT3 inhibitor, Cpd188 combined with 
temozolomide and radiation in vitro assays using two 
established glioblastoma cell lines (U251, U87) and two 
patients-derived glioblastoma cell lines (GBL12, GBL28) and 
in vivo studies using nude mice bearing intracranial U251 
xenografts. 
 
Results: Cpd188 potentiated the radiosensitizing effect of 
TMZ in U251 cell which has high levels of p-STAT3 expression. 
Increased radiosensitizing effects of TMZ were associated 
with impaired DNA damage repair, apoptosis and the 
reversion of epithelial-mesenchymal transition (EMT). Cpd188 
delayed in vivo tumor growth both alone and in combination 
